Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$58.57 USD

58.57
6,497,733

-0.23 (-0.39%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $58.56 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT

Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.

    Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

    Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.

      CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

      CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

        Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?

        Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

          Merck's Keytruda Gets Priority Review in Difficult Lung Cancer

          Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.

            Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod

            The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.

              Incyte (INCY) Announces Positive Results on Jakafi for GVHD

              Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.

                Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive

                AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.

                  Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis

                  Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.

                    Incyte (INCY) Up 10.2% Since Earnings Report: Can It Continue?

                    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates

                      Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.

                        Ekta Bagri headshot

                        Incyte (INCY) Reports A Loss in Q1

                        Incyte reported a loss in the first quarter while sales also beat estimates.

                          Should You Sell Incyte (INCY) Before Earnings?

                          Incyte (INCY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.

                            Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?

                            Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.

                              Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

                              The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

                                Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up

                                Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.

                                  Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                                  Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

                                    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

                                      Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis

                                      The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.

                                        NewLink Shares Plunge After Incyte & Merck's Study Fails

                                        Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.

                                          Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge

                                          Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.

                                            Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue?

                                            Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              AstraZeneca's Final Data From Key Lung Cancer Study Delayed

                                              AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.

                                                The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte

                                                The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte

                                                  Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC

                                                  Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC